NeuroSense Therapeutics Ltd. Ordinary Shares - relatórios financeiros trimestrais (NASDAQ:NRSN) | MetaTrader

Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas

Market Capitalization 23.77 M
Employee 15
Founded 2017
CEO N/A
Website www.neurosense-tx.com
Headquarter Israel
FIGI UNKNOWN
Industry Technology

Total debt

Free cash flow

Cash & equivalents

23.77 M Market capitalization

Notícias

Roth/MKM inicia cobertura da NeuroSense com recomendação de compra devido ao potencial do medicamento para ELA

Roth/MKM initiates NeuroSense stock with buy on ALS drug potential

Ações da Neurosense Therapeutics sobem após garantir patente australiana para PrimeC

Neurosense Therapeutics stock rises after securing Australian patent for PrimeC

Ações da Neurosense sobem após medicamento para Alzheimer mostrar perfil de segurança favorável

Neurosense stock rises as Alzheimer’s drug shows favorable safety profile

NRSN stock touches 52-week high at $1.65 amid robust gains

NRSN stock touches 52-week high at $1.52 amid growth optimism

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - NeuroSense Therapeutics (NASDAQ:NRSN)

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - NeuroSense Therapeutics (NASDAQ:NRSN), Primis Finl (NASDAQ:FRST)